AUD16.38
9.20% today
Australia, Sep 23, 08:10 am CET
ISIN
AU000000TLX2
Symbol
TLX

Telix Pharmaceuticals Stock price

AUD16.38
-2.38 12.69% 1M
-12.82 43.90% 6M
-8.23 33.44% YTD
-4.31 20.83% 1Y
+11.07 208.47% 3Y
+14.62 830.68% 5Y
+15.61 2,027.27% 10Y
+15.61 2,027.27% 20Y
Australia, Closing price Tue, Sep 23 2025
+1.38 9.20%
ISIN
AU000000TLX2
Symbol
TLX
Industry

Key metrics

Basic
Market capitalization
AUD4.9b
Enterprise Value
AUD5.1b
Net debt
AUD211.1m
Cash
AUD207.2m
Shares outstanding
338.4m
Valuation (TTM | estimate)
P/E
500.0 | 32.8
P/S
7.4 | 4.5
EV/Sales
7.7 | 4.7
EV/FCF
negative
P/B
11.7
Financial Health
Equity Ratio
37.5%
Return on Equity
8.8%
ROCE
3.2%
ROIC
4.4%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
AUD664.7m | AUD1.1b
EBITDA
- | AUD199.6m
EBIT
AUD28.2m | AUD150.9m
Net Income
AUD11.0m | AUD154.5m
Free Cash Flow
AUD-24.0m
Growth (TTM | estimate)
Revenue
27.5% | 113.3%
EBITDA
- | -
EBIT
-49.2% | 188.7%
Net Income
-72.0% | 373.0%
Free Cash Flow
-289.8%
Margin (TTM | estimate)
Gross
54.0%
EBITDA
- | 18.3%
EBIT
4.2%
Net
1.7% | 14.1%
Free Cash Flow
-3.6%
More
EPS
AUD0.0
FCF per Share
AUD-0.1
Short interest
-
Employees
423
Rev per Employee
AUD1.2m
Show more

Is Telix Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Telix Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Telix Pharmaceuticals forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a Telix Pharmaceuticals forecast:

Buy
88%
Hold
13%

Financial data from Telix Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
665 665
28% 28%
100%
- Direct Costs 306 306
54% 54%
46%
359 359
11% 11%
54%
- Selling and Administrative Expenses 169 169
25% 25%
25%
- Research and Development Expense 154 154
0% 0%
23%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 28 28
49% 49%
4%
Net Profit 11 11
72% 72%
2%

In millions AUD.

Don't miss a Thing! We will send you all news about Telix Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Christian Behrenbruch
Employees 423
Founded 2017
Website telixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today